Breast–chest difference

Breast–chest difference, also known as bust–band difference, is a measurement used for quantifying breast size. It is calculated as bust circumference minus the band or underbust circumference. Breast–chest difference is used in the determination of bra cup size, with 12–14 cm equating to an A cup, 14–16 cm a B cup, 16–18 cm a C cup, and 18–20 cm a D cup. Breast–chest difference has been used in the measurement of breast development in transgender women on feminizing hormone therapy.[1][2][3][4][5]

Breast–chest difference is the difference of the breast circumference (upper line) and the underbust circumference (lower line).

See also

References
  1. Nolan BJ, Cheung AS (June 2021). "Relationship Between Serum Estradiol Concentrations and Clinical Outcomes in Transgender Individuals Undergoing Feminizing Hormone Therapy: A Narrative Review". Transgend Health. 6 (3): 125–131. doi:10.1089/trgh.2020.0077. PMC 8363983. PMID 34414268.
  2. de Blok CJ, Dijkman BA, Wiepjes CM, Staphorsius AS, Timmermans FW, Smit JM, Dreijerink KM, den Heijer M (January 2021). "Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment". J Clin Endocrinol Metab. 106 (2): e782–e790. doi:10.1210/clinem/dgaa841. PMID 33206172.
  3. de Blok CJ, Klaver M, Wiepjes CM, Nota NM, Heijboer AC, Fisher AD, Schreiner T, T'Sjoen G, den Heijer M (February 2018). "Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study". J Clin Endocrinol Metab. 103 (2): 532–538. doi:10.1210/jc.2017-01927. PMID 29165635.
  4. Meyer G, Mayer M, Mondorf A, Flügel AK, Herrmann E, Bojunga J (February 2020). "Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria". Eur J Endocrinol. 182 (2): 149–156. doi:10.1530/EJE-19-0463. PMID 31751300.
  5. Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher AD, Toye K, Kaufman JM, T'Sjoen G (August 2014). "Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence". J Sex Med. 11 (8): 1999–2011. doi:10.1111/jsm.12571. PMID 24828032.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.